Botulinum Toxin A to Treat Arm Tremor
Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of NT 201 in the Unilateral Treatment of Essential Tremor of the Upper Limb
Sponsor: Merz Pharmaceuticals GmbH
This PHASE2 trial investigates Essential Tremor of the Upper Limbs and is currently completed. Merz Pharmaceuticals GmbH leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Dec 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merz Pharmaceuticals GmbH
For direct contact, visit the study record on ClinicalTrials.gov .